A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
European Journal of Cancer · 2023-03 · 181 · 135-144
DOI: 10.1016/j.ejca.2022.12.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2023-03. Verfasst von Masato Ozaka und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Toky…. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Center Japan, National Cancer Center, Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: masato.ozaka@jfcr.or.jp.
- Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Förderung
- National Cancer Center Japan
- National Cancer Center
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Ozaka, M., Nakachi, K., Kobayashi, S., Ohba, A., Imaoka, H., Terashima, T., Ishii, H., Mizusawa, J., Katayama, H., Kataoka, T., Okusaka, T., Ikeda, M., Sasahira, N., Miwa, H., Mizukoshi, E., Okano, N., Mizuno, N., Yamamoto, T., Komatsu, Y., …, & Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG) (2023). A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). European Journal of Cancer, 181, 135-144. https://doi.org/10.1016/j.ejca.2022.12.014
Vancouver
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). European Journal of Cancer. 2023;181:135-144. doi:10.1016/j.ejca.2022.12.014
BibTeX
@article{Ozaka2023,
author = {Ozaka, Masato and Nakachi, Kohei and Kobayashi, Satoshi and Ohba, Akihiro and Imaoka, Hiroshi and Terashima, Takeshi and Ishii, Hiroshi and Mizusawa, Junki and Katayama, Hiroshi and Kataoka, Tomoko and Okusaka, Takuji and Ikeda, Masafumi and Sasahira, Naoki and Miwa, Haruo and Mizukoshi, Eishiro and Okano, Naohiro and Mizuno, Nobumasa and Yamamoto, Tomohisa and Komatsu, Yoshito and Todaka, Akiko and Kamata, Ken and Furukawa, Masayuki and Fujimori, Nao and Katanuma, Akio and Takayama, Yukiko and Tsumura, Hidetaka and Fukuda, Haruhiko and Ueno, Makoto and Furuse, Junji and Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG), Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG)},
title = {A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)},
journal = {European Journal of Cancer},
year = {2023},
volume = {181},
pages = {135--144},
doi = {10.1016/j.ejca.2022.12.014}
}
EUVIMED